**7. Cardiovascular system**

There are many studies showing that the inclusion of boron and boron compounds as food supplements has a positive effect on the cardiovascular system. It has been reported that it will reduce especially cardiovascular risk factors. Today, however,

the production and use of boron-containing compounds for the treatment of various diseases are popular. Some of these compounds have been reported to cause cardiovascular toxicity in toxicity studies. Boron nitride (BN) nanoparticles and different formulations could be good candidates for biomedicines. Liu et al. reported that BN nanoparticles coated by PEG (BN-PEG) highly were distributed in the heart tissue and caused high toxic effects histopathologically [34–36].

Hexagonal boron nitride nanoparticles (hBNNPs) are nanomaterials that have special chemical properties and candidate therapeutics in medical applications. In Wistar albino rats, it has been determined that hBNNPs increased oxidative stress. In the cardiac tissues, 3200 μg/kg dose of hBNNPs caused a statistically more significant increase in LOOH levels than the controls [37].

It is known that Bortezomib leads to neurological disorders as peripheral neuropathy; however, a study conducted with Bortezomib showed that it decreased the left ventricular ejection fraction, led to cardiomyocyte abnormalities, damaged the cardiomyocyte contraction through decreased ATP [38]. In another study that compared Boronic acid and Epoxyketone Proteasomal-Targeted Drugs found that boronic acid was much more damaging to myocyte [39].
